Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections

NCT ID: NCT01558713

Last Updated: 2012-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intrathecal (i.t.) administration of isobaric bupivacaine, ropivacaine and levobupivacaine with addition of fentanyl for c-section either combined or not with administration of 10 ml of N/S 0,9% epidurally, in order to extent epidural space.Sensory and motor block profile, haemodynamics and side effects were assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Parturients scheduled for elective caesarean section are randomly allocated to 6 groups: they receive double-blindly intrathecal isobaric bupivacaine 10 mg ( Group B), ropivacaine 15mg (Group R) , levobupivacaine 10mg (Group L) combined with 10 μg fentanyl and followed by epidural administration of 10 ml of N/S 0,9% respectively, and isobaric bupivacaine 10 mg ( Group BupivacaineF), ropivacaine 15mg (Group RopivacaineF) , and levobupivacaine 10mg (Group LevobupivacaineF) combined with 10 μg fentanyl without epidural administration of 10 ml of N/S 0,9%. Clinical endpoints are the sensory and motor block profile, haemodynamics (arterial pressure, heart rate) and side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stillborn Caesarean Section

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group BFS

Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%

Group Type ACTIVE_COMPARATOR

Bupivacaine- Fentanyl - Normal Saline

Intervention Type DRUG

Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Group RFS

Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%

Group Type ACTIVE_COMPARATOR

Ropivacaine-Fentanyl-Normal Saline

Intervention Type DRUG

Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Group LFS

Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%

Group Type ACTIVE_COMPARATOR

Levobupivacaine- Fentanyl- Normal Saline

Intervention Type DRUG

Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

BupivacaineF

Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY

Group Type ACTIVE_COMPARATOR

Bupivacaine + Fentanyl

Intervention Type DRUG

Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus

RopivacaineF

Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.

Group Type ACTIVE_COMPARATOR

Ropivacaine + Fentanyl

Intervention Type DRUG

Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.

LevobupivacaineF

Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.

Group Type ACTIVE_COMPARATOR

Levobupivacaine + Fentanyl

Intervention Type DRUG

Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine- Fentanyl - Normal Saline

Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Intervention Type DRUG

Ropivacaine-Fentanyl-Normal Saline

Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Intervention Type DRUG

Levobupivacaine- Fentanyl- Normal Saline

Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus

Intervention Type DRUG

Bupivacaine + Fentanyl

Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus

Intervention Type DRUG

Ropivacaine + Fentanyl

Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.

Intervention Type DRUG

Levobupivacaine + Fentanyl

Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bupivacaine hydrochloride 0.5% ( Marcaine Spinal, 5 mg/ml, AstraZeneca, Missisipi, ON, Canada) Fentanyl, 50μg/ml, Janssen-Cilag, Belgium 0,9% Sodium Chloride Inj. BP, B.BRAUN Melsungen AG, German Ropivacaine 0.75% :( Naropeine 7.5mg/ml, AstraZeneca) Fentanyl: 50μg/ml, Janssen-Cilag, Belgium 0,9% Sodium Chloride Inj. BP, B.Braun Melsungen AG Chirocaine 5mg/ml, Abbot Laboratories, Greece Fentanyl, 50μg/ml, Janssen-Cilag, Belgium 0,9% Sodium Chloride Inj. BP, B.Braun Melsungen AG Bupivacaine hydrochloride 0,5% (Marcaine Spinal, 5mg/ml,AstraZeneca,Missisipi, ON, Canada) Fentanyl, 50μg/ml (Janssen-Cilag, Belgium) Ropivacaine 0,75% :(Naropeine 7,5mg/ml, AstraZeneca) Fentanyl 50μg/ml, Janssen-Cilag, Belgium. Chirocaine 5mg/ml, Abbot Laboratories, Greece. Fentanyl 50μg/ml, Janssen-Cilag, Belgium.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elective cesarean section
* ASA I-II

Exclusion Criteria

* complicated pregnancy (i.e preeclampsia, eclampsia,arterial hypertension, diabetes mellitus)
* abnormal fetal heart rate at the time of admission
* body mass index \> 35 kg/m2
* height \<150cm and \>185 cm
* age \<18 yrs and \>40 yrs
* patients with contraindication to spinal anaesthesia( i.e anticoagulants)
* ASA \>III
* intraoperative excessive bleeding
* patients with previous psychiatric diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Patras

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

SKLAVOU CHRISTINA

Anesthesiologist- MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

KRITON S FILOS, PROFESSOR

Role: STUDY_CHAIR

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Patras

Christina G Sklavou, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Anesthesia and Intensive Care Medicine, University Hospital of Patras

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Patras

Pátrai, Achaia, Greece

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

KRITON S FILOS, PROFESSOR

Role: CONTACT

+302613603341 ext. +30

CHRISTINA G SKLAVOU, MD

Role: CONTACT

+302613603346

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

KRITON S FILOS, PROFESSOR

Role: primary

+302613603342 ext. +30

Christina G Sklavou, MD

Role: backup

+306974337046 ext. +30

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1312010-25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.